Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Waves in the Growing Antiviral Drug Space with its DehydraTECH Technology
Lexaria Bioscience Corp., through its patented DehydraTECH technology, is improving the way many drugs enter the bloodstream In June 2021, the company proved that an antiviral drug enhanced with its technology was effective at inhibiting the COVID-19/SARS-CoV-2 virus With the global antiviral market projected to hit $66.7 billion by 2025, Lexaria plans to capitalize on this growth by pushing its DehydraTECH technology and exploring multiple avenues of related application Today, it is estimated that infectious diseases account for a quarter to one-third of mortality globally. This has mainly been attributed to increased travel, globalization, populated cities, urbanization, and changes in…